- Home
- BCLI vs ALBT Comparison
BCLI vs ALBT Comparison
Compare BCLI & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ALBT
- Stock Information
- Founded
- BCLI 2000
- ALBT 2014
- Country
- BCLI United States
- ALBT United States
- Employees
- BCLI N/A
- ALBT N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCLI Health Care
- ALBT Health Care
- Exchange
- BCLI Nasdaq
- ALBT Nasdaq
- Market Cap
- BCLI 9.9M
- ALBT 7.9M
- IPO Year
- BCLI N/A
- ALBT N/A
- Fundamental
- Price
- BCLI $1.15
- ALBT $3.90
- Analyst Decision
- BCLI Strong Buy
- ALBT
- Analyst Count
- BCLI 1
- ALBT 0
- Target Price
- BCLI $30.00
- ALBT N/A
- AVG Volume (30 Days)
- BCLI 36.5K
- ALBT 46.5K
- Earning Date
- BCLI 03-31-2025
- ALBT 05-30-2025
- Dividend Yield
- BCLI N/A
- ALBT N/A
- EPS Growth
- BCLI N/A
- ALBT N/A
- EPS
- BCLI N/A
- ALBT N/A
- Revenue
- BCLI N/A
- ALBT $486,815.00
- Revenue This Year
- BCLI $170.09
- ALBT N/A
- Revenue Next Year
- BCLI N/A
- ALBT N/A
- P/E Ratio
- BCLI N/A
- ALBT N/A
- Revenue Growth
- BCLI N/A
- ALBT N/A
- 52 Week Low
- BCLI $1.05
- ALBT $2.11
- 52 Week High
- BCLI $11.25
- ALBT $21.60
- Technical
- Relative Strength Index (RSI)
- BCLI 29.12
- ALBT 38.01
- Support Level
- BCLI $1.12
- ALBT $5.18
- Resistance Level
- BCLI $1.28
- ALBT $7.89
- Average True Range (ATR)
- BCLI 0.12
- ALBT 0.60
- MACD
- BCLI -0.02
- ALBT -0.22
- Stochastic Oscillator
- BCLI 6.27
- ALBT 1.97
Stock Price Comparison Chart: BCLI vs ALBT
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.